News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase III (World)
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
Cardio3 BioSciences Announces The Enrolment Of The 240th Patient For Its CHART-1 Phase 3 Clinical Trial For The Treatment Of Heart Failure 12/19/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/19/2014
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study 12/18/2014
Pivotal Phase 3 Study Of GlaxoSmithKline (GSK) Shingles Candidate Vaccine Meets Its Primary Endpoint 12/18/2014
LFB S.A. Announces Achievement Of Patient Enrollment Target For Persept 1 Program For The Evaluation Of Recombinant Factor Seven Efficacy By Prospective Clinical Trials 12/18/2014
Hutchison Medipharma Starts Phase III Trial Of Cancer Drug 12/18/2014
RedHill Biopharma Ltd. (RDHL) Announces First Patients Enrolled In The Phase 3 Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis 12/17/2014
BeyondSpring To Start China-U.S. Phase 3 Trial Of Novel Cancer Drug 12/12/2014
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014
Head-To-Head Psoriasis Study Demonstrates Superiority Of Novartis AG (NVS) Cosentyx™ To Stelara® In Clearing Skin 12/12/2014
Vectura Group plc (VEC.L)’s Investigational Drug/Device Combination VR475 Met Primary Endpoint And Has Shown Significant Clinical Benefit In A Phase 2b/3 Trial In Severe Asthma Patients 12/11/2014
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 12/11/2014
Phase 3 Results From German Breast Group (GBG) Demonstrates Superior Activity In High Risk Early Breast Cancer For Nab-Paclitaxel (Abraxane®) Vs. Solvent-Based Paclitaxel 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 12/10/2014
FDA Grants Breakthrough Therapy Status To Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Ixazomib 12/8/2014
Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen (AMGN)'s NEUPOGEN® 12/8/2014
Shire Release: Phase 3 Guanfacine Hydrochloride Extended Release (GXR) Study Shows Improvement In Core Symptoms Of Attention-Deficit/Hyperactivity Disorder (ADHD) In Children And Adolescents 12/8/2014
Novartis AG (NVS) Copy Of Amgen (AMGN) Cancer Drug Shows Similar Efficacy 12/8/2014
Novartis AG (NVS) Flu Vaccine FLUAD Suspended Following 13 Reported Deaths 12/3/2014
Novartis AG (NVS) Fingolimod Ph3 Trial In PPMS Fails To Meet Primary Goal 12/3/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Positive Regulatory Feedback From European Medicines Agency On Advancing ICT-107 To Phase 3 Program 12/1/2014
AEterna Zentaris (AEZS) And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
Mylan Inc. (MYL), Gilead Sciences, Inc. (GILD) Ink Agreement Covering Non-Exclusive TAF Rights 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Brodalumab Phase 3 Study Met All Primary Endpoints Against Johnson & Johnson (JNJ)'s Stelara 11/26/2014
Onxeo Announces Positive DSMB Recommendation For Its Phase 3 Trial With Livatag® In Primary Liver Cancer 11/24/2014
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets FDA Breakthrough Therapy Designation 11/24/2014
Top 10 Countries For Diabetes Clinical Research 11/21/2014
Celgene (CELG) Receives Positive CHMP Opinion For OTEZLA (apremilast), The First Oral PDE4 Inhibitor For The Treatment Of Patients With Psoriasis And Psoriatic Arthritis 11/21/2014
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/20/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase 3 Study Of Once Daily Envarsus® XR Demonstrating Non-Inferiority Vs. Twice-Daily Tacrolimus In De Novo Kidney Transplant Patients 11/17/2014
Amgen (AMGN) And AstraZeneca PLC (AZN) Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 11/12/2014
FDA Grants QIDP Fast-Track Designation To RedHill Biopharma Ltd. (RDHL)'s Phase 3 H. Pylori Drug RHB-105 11/10/2014
Genmab A/S (GEN.CO) Announces Additional Data From Phase 3 Study Of Ofatumumab As Maintenance Therapy For Relapsed CLL 11/6/2014
Nine Out Of 10 Lost Weight With Novo Nordisk A/S (NVO)'s Obesity Drug Liraglutide 11/5/2014
Celsion Corporation (CLSN) Receives VHP Approval To Initiate OPTIMA Study In Europe 11/5/2014
AstraZeneca PLC (AZN) And Pharmacyclics, Inc. (PCYC) Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers 11/5/2014
Sanofi Pasteur (SASY.PA)'s Investigational Dengue Vaccine Hits Main Goal Showing Efficacy In Phase 3 Trial 11/4/2014
Novo Nordisk A/S (NVO) Release: New Phase 3a Data Demonstrate That 9 Out Of 10 Adults With Obesity Lost Weight With Liraglutide 3 Mg And Clinical Trial Completers Lost An Average Of 9.2% 11/4/2014
Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) To Be PBS Listed For Metastatic Pancreatic Cancer 10/31/2014
CSL Behring Release: Evidence Presented At The 16th Biennial Meeting Of The European Society For Immunodeficiencies (ESID) Supports Individualized Dosing With Hizentra® 10/31/2014
Helsinn Group Release: New Data On Fatigue From ROMANA 1, A Pivotal Phase III Study Of Anamorelin In Advanced NSCLC Patients With Cachexia Presented At 2014 Chicago Multidisciplinary Symposium In Thoracic Oncology 10/30/2014
Novartis AG (NVS) Expects New Heart Failure Drug As "Multi-Blockbuster" 10/29/2014
Lipid Therapeutics' European Partner Dr. Falk Pharma Gmbh Enrolls First Patients Into Pivotal Phase 3 Trial With LT-02, A Novel Therapy For Ulcerative Colitis (UC) 10/29/2014
Alchemia (ACL.AX) Shares Plummet On Failed Colorectal Cancer Trial 10/27/2014
Roche (RHHBY) Release: CHMP Recommends Label Update For Esbriet In Idiopathic Pulmonary Fibrosis, Strengthening Mortality Benefit And Reinforcing Safety Profile 10/24/2014
Novartis AG (NVS)'s AIN457 Meets Primary Endpoint In Two Late Stage Studies 10/23/2014
MorphoSys AG To Receive Milestone Payment For Guselkumab Phase 3 Program 10/23/2014
Immune Pharmaceuticals, Inc. Release: New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease 10/22/2014
Regeneron (REGN), Sanofi (SAN.PA) Begin Pivotal Phase 3 Study For Eczema Drug Dupilumab 10/20/2014
Basilea Pharmaceutica (BSLN.SW) Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study 10/16/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
Novartis AG (NVS)'s Secukinumab Has Consistent Activity In Psoriasis 10/14/2014
AbbVie (ABBV) Announces Late-Breaking Results From Phase 3 Trial Of HUMIRA® (Adalimumab) In Hidradenitis Suppurativa (HS) Patients At The European Academy Of Dermatology And Venereology Congress 10/13/2014
Ipsen (IPN.PA) Announces Positive Results From Phase III Clinical Study Of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered By Subcutaneous Route To Prostate Cancer Patients 10/13/2014
Cardio3 BioSciences Receives Authorization To Enroll Patients In Switzerland In Its Phase 3 Clinical Trial Chart-1 10/13/2014
Smith & Nephew plc (SNN)’s “Spray-On-Skin” For Leg Ulcers Flops In Trial 10/13/2014
Bioniche Life Sciences Inc. (BNC) To Publish Comprehensive Phase 3 Clinical Trial Results In The Journal Of Urology 10/10/2014
Alchemia Announces Database Lock Of Its HA-Irinotecan Pivotal Phase 3 Trial In Metastatic Colorectal Cancer 10/10/2014
InSightec To Share Key Insights And Progress At The 4th Focused Ultrasound International Symposium 10/9/2014
Pinnacle Biologics, A Subsidiary Of Concordia Healthcare Corp (CXR.TO), Announces European Site Initiation Of Phase 3 Bile Duct Cancer Trial Using Photodynamic Therapy With PHOTOFRIN® 10/7/2014
Acacia Pharma Touts Positive Phase 3 Data For APD421 10/7/2014
AnGes MG Inc. Starts Global Phase 3 Clinical Trials Of Collategene® For Critical Limb Ischemia 10/6/2014
Alcobra (ADHD)'s ADHD Drug Metadoxine Meets Goals In Late-Stage Study 10/6/2014
Norgine Enrolls First Patient In The Phase 3 NOCT Study To Evaluate Bowel Cleansing Efficacy Of NER1006, A Novel, Low Volume Bowel Preparation, Vs. Trisulfate 10/3/2014
Novartis AG (NVS) To Roll Out 15 Abstracts At EADV 10/1/2014
SALVAT Announces Positive Top-Line Results From Two Phase 3 Studies Of Its Novel Otic Antibiotic/Steroid Combination Solution In The Treatment Of AOMT With Tympanostomy Tubes 9/29/2014
Helsinn Group Release: Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Shows Significant Increase In Lean Body Mass, Body Weight And Improved Symptoms 9/29/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014
Novartis AG (NVS) Reports Two Positive Phase 3 Trials For Arthritis Drug 9/26/2014
Bausch & Lomb Announces Successful Results From Phase 3 Study Of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% 9/26/2014
Roche (RHHBY)’s Avastin Prolongs Life In Breast Cancer Study 9/25/2014
NicOx SA (COX.PA) Gets Boost From Strong Prospects For Glaucoma Drug Vesneo 9/25/2014
Helsinn Announces That Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Will Be Presented At The 38th European Society For Medical Oncology (ESMO) Congress In 2014 9/25/2014
Alcobra (ADHD) Announces Completion Of All Patient Visits In Phase 3 Clinical Trial Of MDX In Adult ADHD 9/22/2014
TauRx Therapeutics Achieves Enrollment Target For Second Phase 3 Clinical Trial Of LMTX™ In Alzheimer's Disease 9/22/2014
BioTime (BTX) Announces Presentation Of Phase 3 Data At EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 9/19/2014
Novo Nordisk A/S (NVO)'s Diabetes Drug Ryzodeg Effective In Phase 3b Study 9/18/2014
Janssen-Cilag International NV (JNJ) Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adults 9/17/2014
CSL Behring Announces Last Patient Treated In Phase 3 Study Of Fibrinogen Concentrate To Control Bleeding During Aortic Aneurysm Surgery 9/16/2014
Roche (RHHBY) Starts Pivotal Late-Stage Trial For Eye Drug Lampalizumab 9/15/2014
Evotec AG (EVTG.F) Announces Update On DiaPep277® 9/8/2014
Successful Completion Of Phase 3 Program For Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Two More Phase Iii Studies Support The Benefits Of Reslizumab Treatment In Asthma Patients With Eosinophilia 9/8/2014
Boehringer Ingelheim Corporation Release: TONADO™ - Further Lung Function And Quality Of Life Benefits With Tiotropium + Olodaterol Respimat® FDC* In COPD 9/8/2014
Novartis AG (NVS)'s New Heart Drug Cuts Cardiovascular Death Risk By 20 Percent; "Most Exciting Ever" Med Points To Huge Sales 9/4/2014
RedHill Biopharma Ltd. (RDHL) Initiates Phase 3 Study Of RHB-102 For Gastroenteritis 9/3/2014
Final Landmark Trial Confirms Efficacy Of Sanofi (France) (SAN.PA)'s Dengue Vaccine 9/3/2014
Early Phase 3 Data Suggest Sanofi (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
Macrocure (MCUR) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Curexcell In Diabetic Foot Ulcers 9/2/2014
Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Delivers Clinically And Statistically Significant Reduction In Asthma Exacerbations In Two Pivotal Phase 3 Studies 9/2/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On Expansion Of Ongoing RHB-105 Phase 3 Study, Targeting Broadened H. Pylori Indication Authorized By FDA 8/27/2014
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014
AstraZeneca PLC (AZN) Starts Late-Stage Asthma Drug Trial 8/14/2014
Mologen AG (MOLGF.PK): Preparation And Launch Of New Studies Characterized The First Half-Year 2014 8/13/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results 8/13/2014
Cortendo AB: First Patient Enrolled Into Normocort Phase 3 SONICS Trial Following A Successful EU Investigator Meeting 8/12/2014
Novartis AG (NVS) To Tout Heart Failure Data At European Society of Cardiology Congress 2014 8/12/2014
Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 8/11/2014
New Data Shows High Efficacy For Can-Fite BioPharma (CFBI)'s CF101 In Rheumatoid Arthritis And Psoriasis Patients 8/6/2014
Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696 8/5/2014
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK)'s Ofatumumab Meets Primary Endpoint In Late-Stage Study 8/1/2014
Alkermes plc (ALKS) Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 7/30/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 7/18/2014
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease 7/17/2014
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014
Alcobra (ADHD) Completes Patient Recruitment In Phase 3 Clinical Trial Of MDX In Adult ADHD 7/14/2014
FDA Green Lights Starpharma Holdings Ltd's VivaGel Trial Design 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria 7/8/2014
Endo International plc (ENDP), BioDelivery Sciences International (BDSI) Painkiller BEMA® Buprenorphine Effective In Phase 3 Study 7/7/2014
Bayer Inc. Release: Nexavar® (sorafenib tablets) Now Approved In Canada For The Treatment Of Differentiated Thyroid Cancer 7/7/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO) Leukemia Drug Ofatumumab Fails To Meet Main Trial Goal 7/2/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014
H. Lundbeck A/S (LUN.CO)'s Late Stage Trials For Stroke Failed To Meet Primary Endpoint 6/27/2014
Eisai Inc. (ESALF.PK) & Helsinn Group To Present New CINV Research At 2014 International Symposium On Supportive Care In Cancer 6/26/2014
FDA Requests More Data For Basilea Pharmaceutica (BSLN.SW)'s Pneumonia Drug Ceftobiprole; Stock Drops -8.15% At Market Close (June 25, 2014) 6/25/2014
Orexo AB (ORXOF) Release: Top-Line Data From A Phase 3 Clinical Trial Demonstrates That Zubsolv® Is As Effective As Suboxone® Film In The Treatment Of Opioid Dependence 6/25/2014
Agreement On Phase 3 Trial Protocol Of OSE Pharma's OSE-2101 From The FDA And European Medicines Agency 6/24/2014
Positive New Phase 3a Data On Novo Nordisk A/S (NVO)'s Liraglutide 6/23/2014
Orexo AB (ORXOF) Release: Positive Top-Line Results From Two Phase 3 Clinical Trials That Assessed Zubsolv® For Induction Of Buprenorphine Maintenance Therapy 6/23/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014
Boehringer Ingelheim (Canada) Ltd. Release: Study Findings Show Tiotropium Respimat®* Well-Tolerated And Effective In Japanese Patients With Symptomatic Asthma 6/19/2014
Successful Phase 3 Results For Alkermes plc (ALKS)'s Schizophrenia Drug Aripiprazole Lauroxil 6/19/2014
Actelion Ltd. (ALIOF.PK) Soars As Heart-Lung Drug Selexipag Meets Main Goal In Late-Stage Study 6/18/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Novo Nordisk A/S (NVO)'s Big-Selling Diabetes Drug Victoza Appears Effective For Weight Loss 6/16/2014
Sanofi (France) (SAN.PA) Toujeo Shows Great Promise As Lantus Successor 6/16/2014
Novo Nordisk A/S (NVO) Combination Diabetes Drug IDegLira Effective After 1 Year Study 6/16/2014
Eli Lilly and Company (LLY) Release: Type 2 Diabetes: Jardiance® (Empagliflozin) As An Add-On Therapy Significantly Reduced Blood Glucose And Body Weight In Two Newly Presented Phase 3 Trials 6/16/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Tout Positive Phase 3 Data For Rheumatoid Drug Sarilumab 6/13/2014
All Eyes Are On AstraZeneca PLC (AZN) As Its Diabetes Drugs Go Under The Spotlight At Major Scientific Meeting 6/12/2014
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference 6/12/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Put Out Positive Update On Two Phase 3 Ellipta COPD Studies 6/11/2014
EULAR: Romosozumab Significantly Increases Bone Mineral Density And Bone Content Compared With Teriparatide 6/11/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Phase 3 Trial Initiated In Germany 6/10/2014
ALK-Abello A/S Presents Phase 3 Data On House Dust Mite SLIT-Tablet At EAACI Annual Congress In Copenhagen 6/9/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod 6/9/2014
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 6/6/2014
RedHill Biopharma Ltd. (RDHL) Announces New RHB-104 Patent In Japan And Provides Update On Phase 3 Crohn's Program 6/5/2014
Jiangsu Hengrui Medicine Co. Ltd. Reports Positive Phase 3 Data For Cancer Drug 6/4/2014
Dainippon Sumitomo Pharma Co., Ltd. Halts Key Phase 3 Global Colorectal Carcinoma Monotherapy Trial 5/28/2014
RedHill Biopharma Ltd. (RDHL) Announces FDA Clearance For Phase 3 Study With RHB-102 Planned To Commence In Q3/2014 5/22/2014
Santhera Pharmaceuticals AG (SANN.SW) Reports Positive Outcome For Catena®/Raxone® In Phase 3 DMD Trial Supported By Additional Respiratory Function Data 5/22/2014
SOTIO Initiates VIABLE, A Global Phase 3 Clinical Trial For Prostate Cancer Immunotherapy Treatment With DCVAC/PCa 5/22/2014
Boehringer Ingelheim Corporation Stakes Claim To Combination COPD Market As Phase 3 Data For Tiotropium Is Positive 5/22/2014
RedHill Biopharma Ltd. (RDHL) And IntelGenx Corp. Report Positive RHB-103 Bioavailability Study Results In Support Of Planned European Marketing Application In Q3/2014 5/21/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO)' Arzerra Fails Phase 3 Lymphoma Trial 5/21/2014
In The Battle Of Idiopathic Pulmonary Fibrosis Drugs, Boehringer Ingelheim Corporation's Nintedanib Wows In Phase 3 Trial 5/19/2014
Kamada Ltd. (KMDA) Crashes After Key Trial Failure 5/19/2014
GlaxoSmithKline (GSK)'s Once Promising Heart Drug Strikes Out Again 5/14/2014
Basilea Pharmaceutica (BSLN.SW) Reports Additional Data On Positive Isavuconazole Phase 3 SECURE Study At ECCMID 5/14/2014
Mologen AG (MOLGF.PK): Development Of Main Product Candidate Pushed Forward Swiftly In First Quarter 5/14/2014
Santhera Pharmaceuticals AG (SANN.SW) Announces Successful Outcome Of Phase 3 Study With Catena®/Raxone® In Duchenne Muscular Dystrophy 5/14/2014
Gene Signal Announces Positive Data From Phase 3 Trial of Aganirsen Eye Drops For Corneal Neovascularisation Due To Inflammation, A Rare Eye Disease With European Orphan Drug Designation 5/14/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Psoriasis Drug Brodalumab Meets Goals In Phase 3 Study 5/14/2014
Taiho Oncology's TAS-102 Meets Primary Endpoint Of Improving Overall Survival In Global Phase 3 RECOURSE Trial In Refractory Metastatic Colorectal Cancer 5/12/2014
AstraZeneca PLC (AZN) Jumps Start Late-Stage Study Of Key New Cancer Drug 5/9/2014
Immune Pharmaceuticals, Inc. Announces Phase 3 Development And Commercialization Strategy For AMIKET 5/5/2014
Endocyte, Inc. (ECYT), Merck & Co., Inc. (MRK) Halt Study Of Ovarian Cancer Drug Vintafolide; Endocyte Stock Plunges -61.91% At Market Close (May 2, 2014) 5/2/2014
Teva Pharmaceutical Industries Limited (TEVA) Reports Positive Results From Pivotal Phase 3 Study To Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) For Moderate To Severe Chronic Low Back Pain 4/30/2014
RedHill Biopharma Ltd. (RDHL) Reports Successful RHB-102 Bioavailability Clinical Trial And Planned Submission Of European Marketing Application In Q3/2014 4/30/2014
OncoGenex Pharmaceuticals Inc. (OGXI)'s Long Awaited Cancer Drug Ends With A Phase 3 Stumble; Stock Down -60.31% At Market Close (April 28, 2014) 4/30/2014
Cell Therapeutics, Inc. (CTIC) PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 4/29/2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA In Cancer Pain 4/28/2014
IntelGenx Corp. And RedHill Biopharma Ltd. (RDHL) Announce Commencement Of A Bioavailability Study With Anti-Migraine Versafilm™ Product To Support European Marketing Application Planned For Q3/2014 4/28/2014
Merck & Co., Inc. (MRK) Announces Positive Outcome Of 3b Study For Kuvan 4/24/2014
Boehringer Ingelheim Corporation Rethinks Hepatitis Business, Braces For A Rough 2014 4/17/2014
AbbVie (ABBV)'s Experimental Hepatitis C Regimen Associated With High Cure Rates In Late-Stage Studies 4/15/2014
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase III Clinical Trial With Livatag® In Primary Liver Cancer 4/14/2014
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase 3 Clinical Trial With Livatag® In Primary Liver Cancer 4/14/2014
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Blood Disorder Drug Succeeds In Phase 3 Trial 4/10/2014
Alkermes plc (ALKS) Pulls Off Phase 3 Win for Long-Lasting Schizophrenia Drug 4/9/2014
GlaxoSmithKline (GSK) Halts Late-Stage Lung Cancer Vaccine Trial 4/3/2014
Medivir AB (MVRBF) Release: Two Phase 3 Trials Evaluating Once-Daily Simeprevir And Sofosbuvir In Hepatitis C Infected Patients Have Been Initiated 4/2/2014
Novartis AG (NVS) Closes Heart Drug Study Early After Strong Results 4/1/2014
Novartis AG (NVS)'s Rare Lung Cancer Drug Ceritinib Shows Positive Response In Study 3/27/2014
Swedish Orphan Biovitrum Release: Kiobrina Pivotal Phase 3 Study Did Not Meet Primary Endpoint 3/26/2014
CogState Ltd (CGS.AX)'s Technology Chosen For Major Phase 3 Trial Of Alzheimer's Disease Drug 3/25/2014
Novo Nordisk A/S (NVO) Reports Positive Results From First Phase 3 Trial With N8-GP, A Long-Acting Factor VIII For Treatment Of Haemophilia A 3/19/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 3 Clinical Trial For MDX In Adult ADHD 3/18/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Touts Positive Results From Three COPD Phase 3 Studies 3/17/2014
Medivir AB (MVRBF) Release: New Phase 3 Data From Once-Daily Simeprevir Presented At The Conference Of The Asian Pacific Association For The Study Of The Liver (APASL) 3/17/2014
GlaxoSmithKline (GSK) Touts Positive Asthma Drug Results From Two Phase 3 Studies 3/14/2014
CrystalGenomics Announces Positive Results Of Phase 3 Trial Of Polmacoxib (CG100649) In Patients With Osteoarthritis 3/13/2014
Novartis AG (NVS) Drug Jakavi® Gets Tagged As A Potential Blockbuster After Positive Late-Stage Study 3/10/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On RHB-102 Development And Intellectual Property 3/7/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 3/5/2014
LFB S.A. Initiates Global Phase 3 Clinical Trial Of New Coagulation Factor Viia (Recombinant) In Patients With Hemophilia A And B 3/3/2014
Actelion Ltd. (ALIOF.PK)'s Diarrhea Treatment Gets Fast-Track From The FDA 3/3/2014
Sinovac Biotech Ltd. (SVA)'s EV71 Vaccine Phase III Clinical Trial Results Published In The New England Journal of Medicine 2/27/2014
Shire plc Release:” New Phase 3 Data For Guanfacine Extended Release (GXR) To Be Presented At European Congress Of Psychiatry 2/27/2014



//-->